Objective
To employ two non-replicating delivery systems will be employed to deliver antigens to the immune system and to elicit the appropriate protective immune responses against human diseases such as HIV, HCV and tumours. The immune responses and their protective efficacy will be assessed in animal models. The mechanism of CTL activities of these particles and their ability to induce mucosal responses will be studied. Both particles will be further investigated and modified for broader application.
Brief description
Two different self-assembled structures that lack nucleic acid have been developed as immunogen delivery systems during previous EEC funded projects. These are PPV-VLPs and NS1-TUBs and both have been shown to be highly immunogenic. Based on previous data we propose to generate chimeric VLPs and TUBs carrying a selection of T-cell epitopes of HIV-1, HCV and tumour antigens using recombinant baculovirus expression systems and insect cell cultures. Each assembled chimeric particles will be purified and characterised thoroughly at molecular and antigenic levels. Subsequently, these particles will be utilised to investigate their immunogenicity and their capabilities of inducing the appropriate immune responses in in vitro and in vivo model animals. The protective efficacy of each chimeric construct will be further assessed by challenge experiments in pre-clinical studies and for some constructs in clinical studies, if the opportunity becomes available. CTL response by non-replicating particles is a novel approach, and therefore the mechanism of such activity will be investigated in depth using the appropriate constructs. Lastly, each of the delivery systems will be modified by creating additional foreign sequence sites generating multiple chimeric copies by single recombinant vectors, and creating the delivery systems more immunologic by fusion with adjuvant, such as cholera toxin subunit. In addition, both types of particles will be subjected to high purified regimes suitable for human vaccine. The results and the reagents obtained from this project will allow to develop vaccines for other human and animal diseases.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules nucleic acids
- medical and health sciences health sciences infectious diseases RNA viruses hepatitis C
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
LONDON
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.